Home major
 

Keywords :   


Tag: major

Wärtsilä Awarded Five Major Power Plant Projects in Argentina

2016-10-13 01:00:00| Power Technology

Wärtsilä has been awarded five power plant projects, which will support development of the national grid in Argentina.

Tags: power major projects argentina

 

APS Reaches Major Solar Milestone; Tops Gigawatt of Solar Energy

2016-10-12 18:30:00| Transmission & Distribution World

This summer, APS surpassed one gigawatt of solar energy capacity, becoming the only utility outside of California to achieve this milestone read more

Tags: major energy tops solar

 
 

COMLAB Wins a Major Order in Germany

2016-10-11 10:37:00| Railway Technology

COMLAB has won the tender for outfitting approximately 400 Deutsche Bahn (DB) trains with a mobile telecommunications system.

Tags: order major germany wins

 

CME: Major International Buyers Increase US Pork Imports

2016-10-10 02:00:00| ThePigSite - Industry News

US - The USDA-ERS released August monthly trade number yesterday. These meat trade numbers are on a carcass weight basis and are calculated from product weight numbers reported by the US Department of Commerce, write Steve Meyer and Len Steiner.

Tags: international major increase buyers

 

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Mercks KEYTRUDA (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients

2016-10-09 08:16:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 Expression KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology: Language: English Contact: Media:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of range major potential

 

Sites : [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] next »